Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …

The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's
disease and the APOE ε2 allele the strongest genetic protective factor after multiple large …

Background The growing body of evidence indicating the heterogeneity of Alzheimer's
disease (AD), coupled with disappointing clinical studies directed at a fit-for-all therapy …

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

The vast majority of Alzheimer's disease (AD) cases are late onset (LOAD), which is
genetically complex with heritability estimates up to 80%. Apolipoprotein E (APOE) has been …

Alzheimer's disease (AD) is an immutable neurodegenerative disease featured by the two
hallmark brain pathologies that are the extracellular amyloid ß (Aß) and intraneuronal tau …

Recent trials of anti‐amyloid agents have not produced convincing improvements in clinical
outcome in A lzheimer's disease; however, the reason for these poor or inconclusive results …

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that causes
progressive cognitive decline. The majority of AD cases are sporadic and late-onset (> 65 …

There are virtually no clinically available neuroprotective drugs for the treatment of acute
and chronic neurological disorders, hence there is an urgent need for the development of …

High-density lipoproteins (HDL) play a key role in cholesterol homeostasis maintenance in
the central nervous system (CNS), by carrying newly synthesized cholesterol from astrocytes …